Rare, Deadly Lymphoma Demystified

Findings identify a cause of the disease and highlight potential therapeutic approach

ALCL map

A map of mutations observed in ALK-negative anaplastic large cell lymphoma. Please see animation below for further details. (Credit: Dr. Rabadan)

The first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin’s lymphoma (NHL), shows that many cases of the disease are driven by alterations in the JAK/STAT3 cell signaling pathway. The study also demonstrates, in mice implanted with human-derived ALCL tumors, that the disease can be inhibited by compounds that target this pathway, raising hopes that more effective treatments might soon be developed. The study, led by researchers at Columbia University Medical Center (CUMC) and Weill Cornell Medical College, was published today in the online edition of Cancer Cell.

“Current therapies for this form of lymphoma fail to work in the majority of cases. However, now that we know the mutations that drive a significant percentage of cases, we can envision a new, personalized genomic approach to the treatment of ALK-negative ALCL,” said co-study leader Raul Rabadan, PhD, associate professor of systems biology and of biomedical informatics at Columbia University. The other co-study leader is Giorgio Inghirami, MD, of Weill Cornell Medical College.

Genetic map of ALCL

Animation: Genetic map of ALCL. Click to enlarge. (Credit: Columbia University Medical Center).

About 70,000 cases of NHL are diagnosed each year; ALCL accounts for about 3 percent of them. Patients with systemic ALCL (disease that has spread to multiple body sites) fall into two groups, depending on whether their cells express an abnormal form of the ALK (anaplastic lymphoma kinase) protein. ALK-positive lymphomas tend to respond well to chemotherapy, with a long-term disease-free survival rate of more than 70 percent. These lymphomas are known to result from the fusion of two genes, which produces an abnormal protein that activates a third gene, STAT3. Patients with ALK-negative lymphomas have a worse prognosis, with a long-term survival rate of less than 50 percent. Very little is known about the cause of this form of the disease.

To learn more about the genetics of ALCL, Dr. Rabadan and his colleagues sequenced the exomes (the protein-coding portion of the genomes) and the RNA of tumor cells from 155 patients with ALCL and 74 controls (patients with other forms of lymphoma). The team found mutations in either JAK1 or STAT3 in about 20 percent of the 88 patients with ALK-negative ALCL. Of those 20 percent, 38 percent had mutations in both genes.

Either JAK1or STAT3 mutations can cause abnormal activation of the JAK/STAT3 signaling pathway, which transmits chemical signals from outside the cell to genes in the cell nucleus. Overactivation of this pathway has been implicated in various forms of cancer.

https://youtu.be/kdCCap3qNco

The researchers also detected the presence of several novel gene fusions, some of which appear to activate the JAK/STAT3 pathway. Patients with these gene fusions did not have JAK1 or STAT3 mutations, suggesting that the fusions are an independent cause of ALK-negative ALCL.

To confirm whether JAK1 and STAT3 mutations can cause ALK-negative ALCL, the researchers induced these mutations in normal human cells. The mutations led to diseased cells.

Finally, the researchers tested JAK/STAT3 pathway inhibitors in mice implanted with tumors derived from patients with ALK-negative ALCL. Tumor growth was significantly inhibited, compared with controls. “Our findings demonstrate that drugs targeting the JAK/STAT3 pathway offer a viable therapeutic strategy in a subset of patients with ALCL,” said Dr. Rabadan. “A couple of JAK/STAT3 inhibitors have been approved by the FDA for the treatment of psoriasis and rheumatoid arthritis, and several more are currently in clinical trials. These could be tested in patients whose genetic profile matches those we identified in our study.”

Tags

blood cancer, CANCER, Cancer Research, cancer therapy, lymphoma

References

About:

The lead authors of the paper are: Ramona Crescenzo (University of Torino, Torino, Italy, and Weill Cornell Medical College, New York, NY), Francesco Abate (University of Torino; Politecnico di Torino, Torino, Italy, and CUMC), and Elena Lasorsa (University of Torino).

The paper is titled, “Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma.” The other contributors are listed in the paper.

The study was funded by grants from the National Institutes of Health (R01 CA185486, R01 CA179044, and U54 CA121852), the Stewart Foundation, Oncosuisse, Anna Lisa Stiftung, the Nelia and Amadeo Barletta Foundation, and other sources listed in the paper.

The other authors declare no financial or other conflicts of interest.

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.